Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open Label Study of the Safety, Pharmacokinetics and Antiviral Activity of BIT225 in Combination with Pegylated Interferon and Ribavirin in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1.

Next Previous
X
Search
Trial Profile

A Phase 2, Open Label Study of the Safety, Pharmacokinetics and Antiviral Activity of BIT225 in Combination with Pegylated Interferon and Ribavirin in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BIT 225 (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C; HIV infections
  • Focus Adverse reactions
  • Sponsors Biotron

    • Most Recent Events

    • 10 Oct 2014 Results published in Biotron media release.
    • 21 Nov 2013 Interim results published in Biotron media release.
    • 21 Nov 2013 Status changed from active, no longer recruiting to completed, according to a Biotron media release. The trial was completed in mid-2013.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top